Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Percutaneous coronary intervention (PCI) using a paclitaxel-eluting stent system (TAXUS) is more cost effective than coronary bypass

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Boston Scientific Corporation.SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease. Media Release: 20 May 2009. Available from: URL: http://www.bostonscientific.com

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Percutaneous coronary intervention (PCI) using a paclitaxel-eluting stent system (TAXUS) is more cost effective than coronary bypass. Pharmacoecon. Outcomes News 579, 12 (2009). https://doi.org/10.2165/00151234-200905790-00028

    Download citation

    Keywords

    • Coronary Artery Disease
    • Coronary Artery
    • Percutaneous Coronary Intervention
    • Economic Analysis
    • Medical Cost